29 Oct, 2026
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon…
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech…
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Adam Feuerstein is a senior writer and biotech…
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon…
The red-brick nursing home tucked off a busy road in Taunton used to be a rare jewel in a beleaguered industry, polished to a high sheen. Floors gleamed from daily…

GAO should study if TrumpRx saved people money, lawmaker says| STAT

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. A House lawmaker asked the Government Accountability Office to review whether the TrumpRx platform has saved Americans any money. In an Oct. 27 […]

2 mins read

ESMO 2026 news: The presentation everyone’s been waiting for

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout […]

3 mins read

Gilead pays $45 million to settle kickback case filed by Texas AG

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Gilead Sciences agreed to pay $45 million to settle allegations of paying kickbacks that improperly influenced prescriptions paid for by the Texas Medicaid […]

3 mins read